Senesco Expands On Preclinical Multiple Myeloma Findings

Senesco Technologies, Inc. (”Senesco” or the “Company”) (Amex: SNT) announced further details of its continuing preclinical multiple myeloma research. In February 2008, the Company announced results of preclinical animal studies in which Senesco’s Factor 5A technology, encapsulated in nanoparticles, was able to induce apoptosis in multiple myeloma tumors when injected intratumorally.

More: continued here

Filed under: Dermatology on June 10th, 2008